可能使患者处于风险的其他药物包括抗真菌药物、抗病毒药物(如特拉匹韦、阿昔洛韦)[31]Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013;149:152-158.http://archderm.jamanetwork.com/article.aspx?articleid=1392461http://www.ncbi.nlm.nih.gov/pubmed/23560295?tool=bestpractice.com 抗逆转录病毒药物(例如奈韦拉平、阿巴卡韦)、[12]Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49-54.http://www.ncbi.nlm.nih.gov/pubmed/22145749?tool=bestpractice.com[27]Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83:1-9.http://www.ncbi.nlm.nih.gov/pubmed/12636014?tool=bestpractice.com[28]Borras-Blasco J, Navarro-Ruiz A, Borras C, et al. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62:879-888.http://jac.oxfordjournals.org/content/62/5/879.fullhttp://www.ncbi.nlm.nih.gov/pubmed/18653488?tool=bestpractice.com 抗寄生虫药、镇痛药(例如对乙酰氨基酚)、[26]Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-e304.http://www.ncbi.nlm.nih.gov/pubmed/19153164?tool=bestpractice.com 非甾体抗炎药 (NSAID) 和选择性环氧化酶-2 (COX-2) 抑制剂、[29]La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28:917-924.http://www.ncbi.nlm.nih.gov/pubmed/16180941?tool=bestpractice.com[30]Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29:687-696.http://www.ncbi.nlm.nih.gov/pubmed/16872242?tool=bestpractice.com 抗疟药、皮质类固醇、[10]Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=articlehttp://www.ncbi.nlm.nih.gov/pubmed/7477195?tool=bestpractice.com 硫唑嘌呤、甲氧苄啶/磺胺甲噁唑、柳氮磺胺吡啶、[35]Tremblay L, de Chambrun GP, De Vroey B, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis. 2011;5:457-460.http://www.ncbi.nlm.nih.gov/pubmed/21939920?tool=bestpractice.com 别嘌醇、氨甲环酸、[34]Irazabal MP, Martin LM, Gil LA, et al. Tranexamic acid-induced toxic epidermal necrolysis. Ann Pharmacother. 2013;47:e16.http://www.ncbi.nlm.nih.gov/pubmed/23447480?tool=bestpractice.com 精神药物、[32]Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Exp Rev Dermatol. 2013;8:681-692. 氯美扎酮、[19]Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.http://www.ncbi.nlm.nih.gov/pubmed/25672763?tool=bestpractice.com[36]Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25:225-234.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890653/http://www.ncbi.nlm.nih.gov/pubmed/24108082?tool=bestpractice.com 抗肿瘤药物(例如苯达莫司汀、白消安、苯丁酸氮芥)[36]Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25:225-234.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890653/http://www.ncbi.nlm.nih.gov/pubmed/24108082?tool=bestpractice.com 和维 A 酸类药物。[37]Mawson AR, Eriator I, Karre S. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): could retinoids play a causative role? Med Sci Monit. 2015;21:133-143.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301467/http://www.ncbi.nlm.nih.gov/pubmed/25579087?tool=bestpractice.com